Tilray Is Growing 73% Internationally. The Market Is Paying Almost No Attention. Is That a Mistake?

Tilray reported fiscal Q3 2026 sales of $206.7 million, with international cannabis revenue up 73% to just over $24 million, or about 12% of total sales. However, the company remains unprofitable, with beverage sales down 24% and U.S. operations down 20%, underscoring ongoing weakness despite its shift toward a broader consumer-packaged-goods model. The article argues the business overhaul is progressing but is not yet enough to justify a bullish stance.

Analysis

The market is still pricing TLRY like a turnaround optionality story, but the balance sheet and earnings profile say it is still a cash-burn restructuring with brand exposure, not a durable consumer platform. The second-order issue is capital allocation: every quarter spent defending low-quality growth in alcohol or U.S. cannabis is a quarter not spent on de-levering or simplifying the portfolio, which keeps the equity trapped in a dilutive financing loop. That makes the stock more sensitive to financing conditions than to operating headlines.

The international cannabis strength is directionally positive, but the base is too small to alter valuation unless it can scale without dragging incremental margin lower. The real tell is that the businesses with broader consumer reach are weakening, which implies the company is leaning into categories with worse competitive intensity and thinner pricing power. If that mix persists for 2-3 quarters, the market will likely re-rate TLRY less as a growth name and more as a distressed asset with residual brand value.

Contrarianly, the consensus may be underestimating how much of TLRY’s upside is already embedded in a narrative of “eventual profitability.” The more interesting trade is not on earnings beats, but on whether management can show a path to positive free cash flow without asset sales or further dilution over the next 6-12 months. Absent that, even good segment growth can coexist with equity underperformance because the median investor will continue to assign a near-zero terminal multiple to a structurally loss-making model.

Key Decisions for Investors

• Avoid long TLRY on the headline international growth print; use any post-earnings strength to fade into the next 1-2 weeks, as the stock is likely to trade on financing/dilution risk rather than revenue mix.
• If already short TLRY, hold the position for a 3-6 month horizon and trail a tight stop only if management demonstrates sequential operating-margin improvement and positive free cash flow guidance; upside risk is a sudden M&A rumor or asset sale.
• Pair trade: short TLRY vs long NDAQ/NFLX-style quality compounders is not ideal on fundamentals, but within the article’s universe TLRY should be treated as the weak leg of any consumer-discretionary basket until profitability is visible; target 15-25% relative downside over 2 quarters.
• Watch for a capital raise or debt refinancing event over the next 90-180 days; that is the clearest catalyst for downside, and any equity issuance would likely reset the stock lower even if operating metrics stabilize.
• For risk-tolerant accounts, consider a small notional put spread on TLRY with 3-6 month expiry to express the view that the market will eventually reprice the turnaround as a financing story rather than a growth story.